Particle.news
Download on the App Store
7 ARTICLES
·
last mo.

Germany’s Stiko Recommends First Travel Vaccine Against Chikungunya for High-Risk Groups

Responding to a first domestic case, Stiko has issued travel vaccine guidance with two approved vaccines to curb severe Chikungunya illness.

Image
Image
Image
Die Ständige Impfkommission hat erstmals eine Reiseimpfung gegen Chikungunya für bestimmte Personengruppen empfohlen. Unter anderem sollten sich Kinder ab zwölf Jahren, die in Gebiete mit aktuellem Chikungunya-Ausbruch reisen, impfen lassen.

Overview

  • Children aged 12 and older traveling to outbreak regions, long-term and frequent visitors to endemic areas, older adults with risk factors and lab personnel now qualify for vaccination under the new Stiko recommendation.
  • Two vaccines are available: the live-attenuated Ixchiq, restricted to ages 12–59 pending EMA safety review, and the inactivated Vimkunya recommended for all eligible individuals aged 12 and above.
  • The guidance aims to prevent Chikungunya infections, alleviate severe joint pain and avoid prolonged illness and fatalities.
  • On July 7, the Robert Koch Institute confirmed a locally transmitted case near the Franco-German border, highlighting domestic transmission potential.
  • Established Aedes albopictus populations in states including Baden-Württemberg, Hesse and Bavaria, coupled with high summer temperatures, increase the risk of local outbreaks.